Associate Director, Clinical Biomarker Development

The Opportunity:

The Associate Director in Clinical Biomarker Development team, within Translational Medicine will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicine’s oncology pipeline. You will:

• Develop and maintain translational and clinical biomarker strategies to support portfolio assets from phase 1 to phase 3 studies.

• Support the development of biomarker related aspects of the trial design, including assay development, patient sample acquisition, study protocols, clinical biomarker plans, and other regulatory documents.

• Participate in cross-functional teams such as clinical working groups and clinical study execution teams.

• Work with internal translational groups, contract research organizations and collaborators to develop and validate assays for clinical use.

• Manage outsourcing to CROs, oversee development of the scope of work, contracting, budgets, and timelines.

• Collaborate with Clinical Bioinformatics and Cancer Genomics to support analysis of biomarker readouts, presenting outputs to internal and external stakeholders.

Required Skills, Experience and Education:

• Ph.D in cancer biology, cell/molecular biology, genomics or equivalent is required.

• 3+ years of clinical biomarker and/or assay development experience in industry is required.

• Experience and track-record of the development, validation, and clinical implementation of biomarker readouts is required.

• Experience of working with Contract Research Organizations to deliver biomarker readouts is required.

• Excellent scientific and business communication skills, strong interpersonal/collaboration skills and planning skills.

• Ability to think critically and creatively and be able to work independently to determine appropriate resources for resolution of problems.

• Ability to multi-task and thrive in a fast-paced innovative environment.

Preferred Skills:

• Experience with targeted oncology therapies or RAS/MAPK pathway biology.

• Biological understanding of pancreatic, non-small cell lung and/or colorectal cancers is preferred.

• Familiarity with biomarker platforms such as genomic, transcriptomic and proteomic assays.

• Familiarity with analytical software and analytical capabilities for integrating clinical and biomarker datasets.

#LI-EM1 #LI- Hybrid